Adaptimmune Therapeutics (ADAP) Revenue & Revenue Breakdown
Adaptimmune Therapeutics Revenue Highlights
Latest Revenue (Y)
$60.28M
Latest Revenue (Q)
$128.37M
Main Segment (Y)
Development revenue
Adaptimmune Therapeutics Revenue by Period
Adaptimmune Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $60.28M | 122.05% |
| 2022-12-31 | $27.15M | 341.50% |
| 2021-12-31 | $6.15M | 55.36% |
| 2020-12-31 | $3.96M | 252.76% |
| 2019-12-31 | $1.12M | -98.11% |
| 2018-12-31 | $59.51M | 57.28% |
| 2017-12-31 | $37.83M | 166.47% |
| 2016-12-31 | $14.20M | 32.43% |
| 2015-06-30 | $10.72M | 1673.21% |
| 2014-06-30 | $604.63K | 100.00% |
| 2013-06-30 | - | - |
Adaptimmune Therapeutics generated $60.28M in revenue during NA 2023, up 122.05% compared to the previous quarter, and up 101.30% compared to the same period a year ago.
Adaptimmune Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $128.37M | 2160.91% |
| 2024-03-31 | $5.68M | 2336.82% |
| 2023-12-31 | $233.01K | -96.82% |
| 2023-09-30 | $7.32M | 42.67% |
| 2023-06-30 | $5.13M | -89.22% |
| 2023-03-31 | $47.60M | 331.64% |
| 2022-12-31 | $11.03M | 57.39% |
| 2022-09-30 | $7.01M | 26.53% |
| 2022-06-30 | $5.54M | 54.91% |
| 2022-03-31 | $3.58M | 152.29% |
| 2021-12-31 | $1.42M | 17.79% |
| 2021-09-30 | $1.20M | -61.13% |
| 2021-06-30 | $3.10M | 613.13% |
| 2021-03-31 | $434.00K | -71.11% |
| 2020-12-31 | $1.50M | 25.90% |
| 2020-09-30 | $1.19M | 137.65% |
| 2020-06-30 | $502.00K | -34.03% |
| 2020-03-31 | $761.00K | 4.53% |
| 2019-12-31 | $728.00K | 207.17% |
| 2019-09-30 | $237.00K | 50.96% |
| 2019-06-30 | $157.00K | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $1.48M | -96.37% |
| 2018-09-30 | $40.79M | 351.34% |
| 2018-06-30 | $9.04M | 10.27% |
| 2018-03-31 | $8.20M | 91.94% |
| 2017-12-31 | $4.27M | -84.29% |
| 2017-09-30 | $27.18M | 672.08% |
| 2017-06-30 | $3.52M | 23.24% |
| 2017-03-31 | $2.86M | -66.53% |
| 2016-12-31 | $8.54M | 253.31% |
| 2016-09-30 | $2.42M | 636.59% |
| 2016-06-30 | $328.00K | -88.76% |
| 2016-03-31 | $2.92M | -25.94% |
| 2015-09-30 | $3.94M | 100.00% |
| 2015-03-31 | - | -100.00% |
| 2014-12-31 | $2.27M | 47.92% |
| 2014-09-30 | $1.53M | - |
Adaptimmune Therapeutics generated $128.37M in revenue during Q2 2024, up 2160.91% compared to the previous quarter, and up 269.69% compared to the same period a year ago.
Adaptimmune Therapeutics Revenue Breakdown
Adaptimmune Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Development revenue | $60.28M | $27.15M | $6.15M | - | - |
| Development And Service | - | - | - | $3.96M | $1.12M |
Adaptimmune Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Development revenue (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Dec 18 | Sep 18 | Jun 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Development revenue | $7.55M | $5.13M | $47.60M | $11.03M | $7.01M | $5.54M | $3.58M | $1.20M | - | - | - | - | - | - | - | - | - | - | - | - |
| Development And Service | - | - | - | - | - | - | - | - | $3.10M | $434.00K | $1.50M | $1.19M | $502.00K | $761.00K | $728.00K | $237.00K | $157.00K | $1.48M | $1.68M | $9.04M |
| License And Service | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $39.11M | - |
Adaptimmune Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 23: Development revenue (100.00%).
Adaptimmune Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SGMO | Sangamo Therapeutics | $176.23M | $356.00K |
| ADAP | Adaptimmune Therapeutics | $60.28M | $128.37M |
| PIRS | Pieris Pharmaceuticals | $42.81M | - |
| AGIO | Agios Pharmaceuticals | $26.82M | $8.62M |
| MREO | Mereo BioPharma Group | $10.00M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| AFMD | Affimed | $8.28M | $155.00K |
| PLRX | Pliant Therapeutics | $1.58M | - |
| FIXX | Q32 Bio | $1.16M | - |
| CRVS | Corvus Pharmaceuticals | - | - |
| APTO | Aptose Biosciences | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| INKT | MiNK Therapeutics | - | - |
| PDSB | PDS Bio | - | - |
| NKTX | Nkarta | - | - |
| LPTX | Leap Therapeutics | - | - |
| ACET | Adicet Bio | - | - |
ADAP Revenue FAQ
What is Adaptimmune Therapeutics’s yearly revenue?
Adaptimmune Therapeutics's yearly revenue for 2023 was $60.28M, representing an increase of 122.05% compared to 2022. The company's yearly revenue for 2022 was $27.15M, representing an increase of 341.50% compared to 2021. ADAP's yearly revenue for 2021 was $6.15M, representing an increase of 55.36% compared to 2020.
What is Adaptimmune Therapeutics’s quarterly revenue?
Adaptimmune Therapeutics's quarterly revenue for Q2 2024 was $128.37M, a 2160.91% increase from the previous quarter (Q1 2024), and a 2402.43% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $5.68M, a 2336.82% increase from the previous quarter (Q4 2023), and a -88.07% decrease year-over-year (Q1 2023). ADAP's quarterly revenue for Q4 2023 was $233.01K, a -96.82% decrease from the previous quarter (Q3 2023), and a -97.89% decrease year-over-year (Q4 2022).
What is Adaptimmune Therapeutics’s revenue growth rate?
Adaptimmune Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 880.34%, and for the last 5 years (2019-2023) was 5272.64%.
What are Adaptimmune Therapeutics’s revenue streams?
Adaptimmune Therapeutics's revenue streams in c 23 are Development revenue
What is Adaptimmune Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Adaptimmune Therapeutics was Development revenue. This segment made a revenue of $60.28M, representing 100.00% of the company's total revenue.